Patent ID: 7655690

Claim:
A sulfonamide of general formula (Ia), wherein R 1 represents a —NR 7 R 8 radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system, R 2 , R 3 , R 4 , R 5 and R 6 , identical or different, each represent hydrogen, halogen, cyano, nitro, a saturated or unsaturated, linear or branched aliphatic radical, a linear or branched alkoxy radical, a linear or branched alkylthio radical, hydroxy, trifluoromethyl, a saturated or unsaturated cycloaliphatic radical, an alkylcarbonyl radical, a phenylcarbonyl or a —NR 9 R 10 group, R 7 and R 8 , identical or different, each represent hydrogen or a saturated or unsaturated, optionally at least mono-substituted linear or branched aliphatic radical, with the proviso that R 8 and R 9 are not hydrogen at the same time, and if one of them, R 8 or R 9 , is a saturated or unsaturated, linear or branched, optionally at least mono-substituted C 1 -C 4 aliphatic radical, the other one is a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical with at least five carbon atoms, or R 7 and R 8 , together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing heterocyclic ring which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system, R 9 and R 10 , identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or R 9 and R 10 , together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing heterocyclic ring which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system, A and B, identical or different, each represent a saturated or unsaturated, linear or branched aliphatic radical, optionally at least mono-substituted or A and B, together with the carbon atom to which they are bonded, form a saturated or unsaturated, but not aromatic cycloalkyl ring, optionally at least mono-substituted and n is 0, or a pharmaceutically acceptable salt thereof.